Failure Investigation SOP and Report Template

In short: This example SOP template helps QA and process owners document a failure, assess possible product and batch impact, determine a supported cause and track follow-up actions. Adapt its roles, forms, escalation and disposition steps to the site’s approved quality system. For FDA-regulated U.S. drug operations, 21 CFR 211.192 includes specific investigation and record requirements; other jurisdictions have their own requirements.

Objective

Describe a documented process for assessing a failure in a product, process, utility or quality system against approved specifications, procedures or acceptance criteria.

Scope

Use this template for failures outside the laboratory’s dedicated out-of-specification (OOS) test-result process. Examples in the source SOP include an in-process test failure, an environmental-monitoring or wash-water result outside an established criterion, a utility that does not meet its approved requirements, and a process-related event.

A laboratory OOS result should be handled through the site’s approved OOS procedure. If evidence suggests a manufacturing or process cause, coordinate the laboratory investigation with a broader product and process impact assessment. FDA’s OOS guidance is nonbinding and addresses chemistry-based testing of drugs regulated by CDER; it describes an initial laboratory assessment and, where laboratory error is not established, a full-scale investigation that includes production review. Do not use that U.S. guidance as a substitute for local requirements or a site’s approved OOS procedure. FDA Guidance for Industry, OOS Test Results, Revision 1 (May 2022).

For FDA-regulated operations, 21 CFR 211.192 requires a thorough investigation of unexplained discrepancies and batch or component failures against specifications, whether or not the batch was distributed. It also requires the investigation to extend to other potentially associated batches or products and a written record of conclusions and follow-up. 21 CFR 211.192, current eCFR.

Responsibility

Assign responsibilities in the controlled site procedure. Investigators should understand the activity and be able to collect and evaluate relevant evidence; QA should oversee the investigation and ensure that the final report and proposed actions receive the review required by the site’s quality system.

Example in-house criterion (not a pharmacopoeial requirement): The source SOP assigns preparation to an Officer QA, review to an Executive QA and approval to the Head QA. Confirm the current role names, authority and approval sequence before adopting them.

Procedure

The steps below are an illustrative workflow. Follow the site’s approved procedures for event reporting, OOS handling, containment, batch disposition, CAPA and document control.

1. Report and record the event

1. Notify the responsible supervisor and QA through the approved escalation route.
2. Record when and how the issue was detected, the affected activity, product or system, relevant batch or equipment identifiers, the requirement that was not met and the immediate actions already taken.
3. Preserve relevant original records, instrument outputs, samples and material where appropriate. Record the source and handling of evidence.
4. Avoid assigning a cause before the evidence has been reviewed.

2. Apply immediate controls

QA and the responsible process owner should assess whether the activity should be stopped, material segregated, a batch placed on hold or other temporary controls applied. Record the rationale, owner and subsequent review of each control.

Example in-house criterion (not a pharmacopoeial requirement): The source SOP directs the QA Head to quarantine potentially affected finished product and hold batches containing reworked material until investigation and a decision are complete. Confirm the conditions, authority and release process in the site’s approved procedures.

3. Define the investigation

Assign an investigator or team with appropriate knowledge of the process. Set the investigation objective, questions, responsibilities, evidence sources and expected report content. Scale the investigation to the event and its possible impact, and document why the scope is adequate.

Review the records and systems that could have contributed to or been affected by the event. Depending on the failure, relevant evidence may include batch and laboratory records, process parameters, equipment and utility records, materials, training, procedures, maintenance, previous events and environmental data. Distinguish observations from hypotheses and evaluate plausible causes against evidence.

For U.S. drug operations subject to 21 CFR 211.192, the investigation must extend to potentially associated batches of the same product and other products. The site should document the batch or product scope considered and the reasons for including or excluding items.

Example in-house criterion (not a pharmacopoeial requirement): The source SOP calls for checking earlier batches made during a manufacturing campaign and separately extending the review to all potentially affected batches or products. Confirm how the campaign window and related products are identified under the site’s approved impact-assessment process.

4. Evaluate OOS and out-of-trend results

Route a laboratory OOS result through the approved laboratory OOS procedure. Do not invalidate a result or attribute it to analytical error without the investigation and evidence required by that procedure. If a laboratory cause is not established, assess potential manufacturing causes and related batches using the approved process.

Example in-house criterion (not a pharmacopoeial requirement): The source SOP directs staff to use this failure-investigation workflow for out-of-trend (OOT) results. Confirm whether OOT events follow this process or a separate trending procedure, and define the relevant escalation and assessment criteria in the site’s controlled system.

5. Assess impact and document the conclusion

Assess the potential effect on product quality and any other relevant patient or product risks. Consider whether the issue could affect other lots, products, operations or records. State what the evidence supports, what remains uncertain and whether additional action is needed.

For any product or batch decision, use the applicable product requirements and approved disposition process. A process failure does not by itself establish one universal disposition for every batch; the quality decision must consider the investigation evidence and applicable requirements.

Example in-house criterion (not a pharmacopoeial requirement): The source SOP states that a laboratory OOS result attributed to a manufacturing failure leads to batch rejection. Verify this as a site-specific disposition rule before retaining it; do not apply it as a universal regulatory rule.

6. Set and follow up corrective action

Where the investigation identifies a cause or a broader system weakness, assign corrective and preventive actions as appropriate under the site’s approved CAPA procedure. Each action should have an owner, due date and documented completion evidence. Record how the site will assess whether the action addressed the cause and prevented recurrence. Do not close actions until the required review is complete.

7. Approve and communicate the report

The report should identify the event, scope, evidence reviewed, assessment of potential impact, investigation findings, supported cause or remaining uncertainty, batch or product decisions, actions and follow-up. Obtain the approvals required by the site’s controlled procedure and communicate the approved outcome to the relevant groups.

Maintain the related event log and supporting records so the investigation can be traced to the affected activity and any related batches.

8. Use a controlled investigation identifier

Example in-house criterion (not a pharmacopoeial requirement): The source SOP uses the pattern FIR / sequential number / calendar year, with sequence numbers from 001 to 099 and an example of FIR / 001 / 2022. Confirm the active document-control convention and uniqueness checks before using this format.

Records and retention

Keep the event report, supporting evidence, investigation and impact assessments, approvals, batch or product disposition, CAPA records, training records and event-log entry in the approved document system. Keep the original data available and preserve traceability when a record is corrected or supplemented.

Retain batch-associated GMP records for at least 1 year after the expiry date of the respective product batch. Under EU GMP Part I, Chapter 4, §4.11, retain batch documentation for at least 5 years after QP certification where that period is longer. Follow any longer period required by local law, the marketing authorisation or the approved site schedule. See EudraLex Volume 4, Part I, Chapter 4, Revision 1 (effective 30 June 2011), §4.11 and 21 CFR 211.180(a), current eCFR.

Training

Train investigators, process owners and reviewers on the approved site procedure, relevant escalation routes, evidence handling, report completion and CAPA follow-up before they perform their assigned responsibilities. Document training in the site’s training system.

Distribution and annexures

The controlled document owner should identify current distribution groups and link the approved forms and procedures used by the site. The imported source listed a failure investigation report, a batch-failure checklist and a failure-investigation log; retain those annexures only if current approved versions exist.

Abbreviations

• CAPA: Corrective action and preventive action
• FIR: Failure investigation report
• OOS: Out of specification
• OOT: Out of trend
• QA: Quality assurance

See also: CAPA process and instructions, laboratory incident SOP, OOS investigation Phase I and Phase II.

References

• U.S. Food and Drug Administration, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production, Guidance for Industry, Level 2 Revision 1 (May 2022): official guidance page and official PDF.
• United States, 21 CFR 211.192, “Production record review,” eCFR version up to date as of 14 October 2026: official regulation.
• European Commission, EudraLex Volume 4, Part I, Chapter 4, “Documentation,” Revision 1 (effective 30 June 2011), §4.11: official PDF.
• United States, 21 CFR 211.180(a), “General requirements,” eCFR version up to date as of 14 October 2026: official regulation.

Revision history